<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Fri, 23 Jan 2026 06:23:22 +0000</lastBuildDate>
    <item>
      <title>#1 [82/100] Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41564691/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41564691/</guid>
      <dc:creator>Lovett JT, Wotman MT, Westra WH, Ahn S, Gupta V, Bakst RL, Roof S, Miles BA, Genden E, Misiukiewicz K, et al.</dc:creator>
      <pubDate>Mon, 19 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 82/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study reports long-term outcomes from a phase III randomized controlled trial on de-escalation strategies for HPV-positive oropharyngeal cancer, addressing a critical need for minimizing toxicity while maintaining efficacy, which could influence treatment guidelines.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Lovett JT, Wotman MT, Westra WH, Ahn S, Gupta V, Bakst RL, Roof S, Miles BA, Genden E, Misiukiewicz K, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107858'&gt;10.1016/j.oraloncology.2026.107858&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-19&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41564691/'&gt;41564691&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: The rising incidence of HPV-positive oropharynx cancer (HPV-OPC) underscores the need for treatment strategies that maintain disease control while minimizing long-term toxicity. This study reports the long-term follow-up of de-escalation in poor prognosis HPV-OPC, providing critical data for future studies. OBJECTIVE: To evaluate long-term outcomes in patients with locally advanced HPV-OPC treated with induction chemotherapy (IC) followed by reduced-dose chemoradiation (rdCRT). We hypothesized that de-escalated radiation therapy after IC would be non-inferior to standard-dose CRT (sdCRT). DESIGN: Two sequential clinical trials; Quarterback (QB) 1: phase III randomized control trial, QB 2: phase II non-randomized trial; patient accrual conducted between December 2012 and February 2022; final data cutoff April 2025. Median follow-up (IQR): 88.5 (64.6-118.2) months. SETTING: Single-institution academic center. PARTICIPANTS: 62 patients with HPV-OPC were screened. 47 patients received rdCRT after IC and were included in the primary analysis. Key eligibility: smoking history¬†‚â§20 pack-years, no active smoking, no distant metastases, molecularly confirmed HPV status. INTERVENTIONS: Three cycles of induction TPF (docetaxel, cisplatin, 5-fluorouracil) followed by rdCRT (5600¬†cGy) with weekly carboplatin in clinical responders; non-responders in both QB trials and responders in the control arm of QB1 received sdCRT (7000¬†cGy). MAIN OUTCOMES AND MEASURES: Primary endpoints: 3-year locoregional relapse-free survival (LRRFS) and 3-year progression-free survival (PFS). Secondary: overall survival (OS). Tertiary: disease-specific survival. RESULTS: Among 47 patients treated with rdCRT after IC, the 3-year and 5-year LRRFS were 89.3% and 86.6%. PFS was 87.2% and 84.6% at 3 and 5¬†years. OS was 91.5% and 89.1% at 3 and 5¬†years. Six patients (13%) experienced locoregional failure, and two (4%) developed distant metastases. 7/8 treatment failures (87.5%) occurred in patients with extracapsular extension. CONCLUSIONS AND RELEVANCE: rdCRT following IC yields durable disease control in poor prognosis HPV-OPC, with outcomes comparable to historical benchmarks. Extended follow-up supports the safety and efficacy of this de-escalation strategy, even in patients with aggressive disease characteristics, but also underscores the need for careful patient selection, particularly in those with extracapsular extension.</description>
    </item>
    <item>
      <title>#2 [75/100] Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41570275/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41570275/</guid>
      <dc:creator>Mirghani H, Aup√©rin A, Even C, Larive A, Fayette J, Geoffrois L, Clatot F, Calderon B, Tao Y, Nguyen F, et al.</dc:creator>
      <pubDate>Thu, 22 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter randomized phase II trial evaluates the feasibility and safety of nivolumab before chemoradiation in a high-risk HPV-positive oropharyngeal cancer population, presenting important insights that could influence future treatment strategies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Mirghani H, Aup√©rin A, Even C, Larive A, Fayette J, Geoffrois L, Clatot F, Calderon B, Tao Y, Nguyen F, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of clinical oncology : official journal of the American Society of Clinical Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1200/JCO-25-00835'&gt;10.1200/JCO-25-00835&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41570275/'&gt;41570275&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Patients with human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) and advanced stage and/or significant smoking history are at higher risk of relapse. Induction immunotherapy before chemoradiation (CRT) may improve outcomes. This randomized phase II trial assessed the feasibility and safety of induction nivolumab before CRT in this high-risk population. METHODS: Eligible patients had HPV-positive OPC with either T4 and/or N2/N3 disease or a smoking history &gt;10 pack-years. Patients were randomly assigned 1:2 to receive either standard CRT (70 Gy with cisplatin, control arm [CA], n = 20) or two infusions of nivolumab followed by CRT (experimental arm [EA], n = 41). The primary end point was the rate of patients who received full treatment in due time (FTDT), defined as (1) two nivolumab infusions on days 1 and 13-17, (2) CRT started between days 27-37 after the first nivolumab infusion, (3) no radiotherapy break ‚â•7 days, (4) &gt;95% of theoretical/prescribed RT dose, and (5) cisplatin dose received ‚â•200 mg/m2. If two patients or less in the EA failed FTDT, the strategy would be considered feasible. Secondary end points included oncologic outcomes and toxicity. RESULTS: Between July 2019 and September 2021, 62 patients were randomly assigned. Median follow-up was 37.5 months. The primary end point was not met: four of 41 patients in EA received &lt;200 mg/m2 cisplatin. Grade 4 to 5 acute adverse events occurred only in EA, in seven patients. The 2-year cumulative incidence (95% CI) of relapse was 7.3% (1.9 to 18.0) in EA versus 15.0% (3.6 to 34.0) in CA. CONCLUSION: Induction nivolumab before CRT did not meet the predefined feasibility threshold because of reduced cisplatin dosing after toxicity in 10% of patients. The relapse incidence was numerically lower in the EA but this finding is exploratory and requires confirmation.</description>
    </item>
    <item>
      <title>#3 [75/100] Prognostic Value of Tumor-Informed Circulating Tumor DNA in HPV-Independent Head and Neck Squamous Cell Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41569592/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41569592/</guid>
      <dc:creator>Ruiz-Torres DA, Roberts TJ, Du P, Mendel J, Neagele S, Bonora G, Zhang F, Efthymiou V, Merkin RD, Lin DT, et al.</dc:creator>
      <pubDate>Thu, 22 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study evaluates the clinical utility of a tumor-informed ctDNA-based MRD assay in a significant patient population with HPV-independent HNSCC, addressing an important clinical question and potentially influencing management strategies, though it is not a randomized trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ruiz-Torres DA, Roberts TJ, Du P, Mendel J, Neagele S, Bonora G, Zhang F, Efthymiou V, Merkin RD, Lin DT, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.4837'&gt;10.1001/jamaoto.2025.4837&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41569592/'&gt;41569592&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: Recurrence rates for locally advanced human papillomavirus (HPV)-independent head and neck squamous cell carcinoma (HNSCC) are high. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assays have shown promise to improve management and surveillance in several tumor types, but their clinical utility in HPV-independent HNSCC remains understudied. OBJECTIVE: To evaluate the performance of a tumor-informed ctDNA-based MRD assay in patients with newly diagnosed locally advanced HNSCC. DESIGN, SETTING, AND PARTICIPANTS: Between December 2020 and March 2022, among patients newly diagnosed with locally advanced HNSCC treated with surgery followed by risk-adjusted adjuvant treatment at a large referral center specializing in treatment of HNSCC, ctDNA was assessed before surgery, before the start of adjuvant treatment, within 6 weeks of completion of treatment, and during surveillance. Patients were followed up for at least 12 months after treatment completion. Kaplan-Meier survival analyses were used to compare recurrence-free survival (RFS) and overall survival (OS) between patients who were MRD positive and those who were MRD negative during each time window. Multivariable Cox hazard regressions were used to assess the association between MRD status and outcomes while controlling for established risk factors. Data were analyzed from August 2024 to March 2025. INTERVENTION: Tumor-informed ctDNA-based MRD testing. MAIN OUTCOMES AND MEASURES: RFS and OS. RESULTS: Of 40 included patients, 29 (73%) were male, 38 (95%) had HPV-independent disease, and the median (IQR) age at diagnosis was 63 (28-85) years. A total of 142 samples from 40 patients. A total of 20 patients (50%) experienced recurrence. The presurgery ctDNA detection rate was 97% (35 of 36). MRD positivity within 6 weeks of completion of treatment was associated with worse OS (hazard ratio [HR], 7.15; 95% CI, 1.44-35.34) and RFS (HR, 5.39; 95% CI, 1.98-21.07). MRD positivity during surveillance was associated with worse RFS (HR, 8.27; 95% CI, 2.03-33.64). The median (range) time from first MRD detection to clinical detection of recurrence was 5 (0.2-21.6) months. In multivariable analyses, MRD positivity was associated with worse RFS (HR, 13.84; 95% CI, 2.92-65.68) and worse OS (HR, 18.93; 95% CI, 2.27-157.70). CONCLUSIONS AND RELEVANCE: In this study, tumor-informed ctDNA MRD positivity was associated with worse RFS and OS in patients with HNSCC. MRD testing could serve as a noninvasive, prognostic biomarker in patients with HPV-independent HNSCC.</description>
    </item>
    <item>
      <title>#4 [75/100] Clinical Significance for risk stratification of papillary thyroid cancer by TUMORFISHER circulating tumor cells technique.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41543346/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41543346/</guid>
      <dc:creator>Jiang L, Li X, Ma T, Zeng P, Tan Z, Zheng C, Xu J, Zhang L, Guo Y, Liang J, et al.</dc:creator>
      <pubDate>Fri, 16 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This prospective study with a substantial sample size of 210 patients provides novel insights into preoperative risk stratification for papillary thyroid cancer using circulating tumor cells, which could influence treatment planning and clinical practice.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Jiang L, Li X, Ma T, Zeng P, Tan Z, Zheng C, Xu J, Zhang L, Guo Y, Liang J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Clinical cancer research : an official journal of the American Association for Cancer Research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/1078-0432.CCR-25-2694'&gt;10.1158/1078-0432.CCR-25-2694&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41543346/'&gt;41543346&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Preoperative risk stratification for papillary thyroid cancer (PTC) is a significant clinical challenge, as current systems primarily rely on postoperative pathology, limiting their utility for initial treatment planning. This study aimed to evaluate the effectiveness of using circulating tumor cells (CTCs) as a non-invasive liquid biopsy tool to stratify patient risk preoperatively. EXPERIMENTAL DESIGN: We conducted a prospective study evaluating preoperative CTC levels in 210 patients diagnosed with PTC. A dual-threshold model was developed to analyze the diagnostic performance of CTC counts. The study particularly focused on the Papillary Thyroid Microcarcinoma (PTMC) subgroup (n=100) to address clinical uncertainty regarding active surveillance versus definitive therapy. Patients were monitored over a median follow-up period of 44 months to assess progression-free survival (PFS) and long-term prognostic outcomes. RESULTS: The dual-threshold model demonstrated excellent diagnostic performance. A cutoff of ‚â• 2 CTCs effectively identified high-risk patients with 93.2% specificity and 88.2% positive predictive value (PPV). In the PTMC cohort, a CTC count &lt; 2 reliably identified low-risk patients suitable for active surveillance (NPV=94.0%), while a count ‚â• 2 pinpointed those with high-risk features warranting surgery (Specificity=96.4%, PPV=80.0%). Prognostic analysis revealed that CTC-negative patients had improved PFS. This was most significant in the PTMC subgroup, where the CTC-negative cohort remained recurrence-free and showed significantly longer PFS compared to CTC-positive cases (HR=0.035, 95% CI: 0.002-0.726; P=0.030). CONCLUSIONS: Preoperative CTC detection enables precise risk stratification for PTC patients. This liquid biopsy approach allows clinicians to personalize therapy-confidently selecting conservative management for low-risk individuals and recommending aggressive treatment for high-risk patients-thereby optimizing clinical decision-making and long-term outcomes.</description>
    </item>
    <item>
      <title>#5 [75/100] Five-year comparison of magnetic resonance imaging and endoscopy for nasopharyngeal carcinoma detection among high-risk populations undergoing screening.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41548058/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41548058/</guid>
      <dc:creator>Zhou HN, Li T, Peng YN, Li H, Wu ZC, Fan YY, King AD, Hildesheim A, Ling W, Liu Z, et al.</dc:creator>
      <pubDate>Thu, 15 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a prospective population-based study with a significant sample size focusing on the detection of nasopharyngeal carcinoma, which has important clinical implications for screening high-risk populations. While it may not be practice-changing, it provides valuable insights into the effectiveness of MRI compared to endoscopy.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Zhou HN, Li T, Peng YN, Li H, Wu ZC, Fan YY, King AD, Hildesheim A, Ling W, Liu Z, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/cncr.70256'&gt;10.1002/cncr.70256&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-15&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41548058/'&gt;41548058&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: The long-term impact of magnetic resonance imaging (MRI) on nasopharyngeal carcinoma (NPC) detection in screening remains unclear as a result of limited follow-up. METHODS: A prospective population-based screening study was conducted in Southern China from October 2014 to November 2018 among Epstein-Barr virus (EBV)-seropositive individuals aged 30-69 years. EBV-seropositive participants underwent both endoscopy and MRI. Suspicious findings from either modality triggered a second endoscopy with biopsy. Followup for cancer diagnoses was completed via multiple methods in October 2023. Primary end points included the 5-year NPC detection rate (overall and by stage) and the false-negative rate. Secondary end points were sensitivity, specificity, positive predictive value (PPV), and referral rate. RESULTS: The analysis included 814 individuals (455 females; 56%) with a median age of 53 years (interquartile range, 46-60 years). Thirty-two NPC cases were detected (30 via MRI; 21 via endoscopy) over 5 years. MRI showed a significantly higher overall NPC detection rate (36.9 [95% CI, 25.9-52.1] vs. 25.8 [95% CI, 16.9-39.1] per 1000; p¬†=¬†.007) and early-stage tumor detection (20.9 [95% CI, 13.1-27.1] vs. 12.3 [95% CI, 6.7-22.5] per 1000; p¬†=¬†.020) than endoscopy. MRI also demonstrated a lower false-negative rate (3.0 [95% CI, 0.8-11.0] vs. 14.9 [95% CI, 8.4-26.5] per 1000; p¬†=¬†.024) and higher sensitivity (93.8% vs. 65.6%; p¬†=¬†.007) but lower specificity (84.0% vs. 92.8%; p¬†&lt;¬†.001) and PPV (19.6% vs. 27.6%; p¬†=¬†.019). CONCLUSIONS: Single MRI demonstrated superior NPC detection versus endoscopy, particularly for early-stage tumors, in high-risk populations during a 5-year period, which suggests the potential for extending the rescreening interval to 5 years for MRI-negative individuals.</description>
    </item>
    <item>
      <title>#6 [70/100] ZNF683+ NK cells govern chemotherapy sensitivity in advanced HPSCC via reshaping immune microenvironment.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41565699/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41565699/</guid>
      <dc:creator>Li G, Xiao W, Wu H, Liu C, Gong L, Zhang H, Shao Z, Bai J, Xia X, Yi X, et al.</dc:creator>
      <pubDate>Wed, 21 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes advanced single-cell RNA sequencing to uncover immunological mechanisms of chemoresistance in hypopharyngeal squamous cell carcinoma, providing important insights into potential predictive biomarkers for chemotherapy response, although it is primarily a novel exploratory study rather than a large-scale clinical trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Li G, Xiao W, Wu H, Liu C, Gong L, Zhang H, Shao Z, Bai J, Xia X, Yi X, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature communications | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41467-026-68676-x'&gt;10.1038/s41467-026-68676-x&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-21&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41565699/'&gt;41565699&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Hypopharyngeal squamous cell carcinoma (HPSCC), an aggressive head and neck cancer with dismal prognosis, faces persistent chemoresistance to standard TPF (docetaxel, cisplatin, 5-fluorouracil) regimen. However, the immunological mechanisms underlying chemoresistance remain undefined. Here, we perform longitudinal single-cell RNA sequencing (scRNA-seq) profiling of paired pre-/post-TPF HPSCC specimens, mapping immune cell dynamics underlying chemoresistance. Our study identifies ZNF683+ natural killer (NK) cells as a gatekeeper of chemotherapy efficacy through integrated single-cell transcriptomics, spatial multiplex immunohistochemistry and functional validation. Moreover, pretreatment baseline enrichment of ZNF683+ NK cells predicts TPF response, while GZMK+CD8+ effector memory T cells function as the predominant immunologic effector to successful TPF intervention. Mechanistically, bioinformatics and in vitro coculture data reveal that ZNF683+ NK cells directly interact with CD8+ T cells, and drive an MHC-I-dependent licensing of polyfunctional GZMK+CD8+ effector memory T cells. Collectively, this NK-CD8+ axis provides a potential predictive biomarker and therapeutic target to overcome chemoresistance in patients with HPSCC.</description>
    </item>
    <item>
      <title>#7 [70/100] Cervical lymph node metastasis in oral squamous cell carcinoma: From metastatic patterns and risk factors to the development and validation of a predictive model.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41564692/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41564692/</guid>
      <dc:creator>Wang XH, Cao LM, Zhu ZQ, Xiao Y, Luo HY, Wang GR, Zhou K, Yu YF, Jia J, Liu B, et al.</dc:creator>
      <pubDate>Tue, 20 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large retrospective analysis with over 3700 patients and develops a predictive model for cervical lymph node metastasis in oral squamous cell carcinoma, which has clinical implications for risk assessment, though it lacks prospective validation and is from a single center.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Wang XH, Cao LM, Zhu ZQ, Xiao Y, Luo HY, Wang GR, Zhou K, Yu YF, Jia J, Liu B, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107860'&gt;10.1016/j.oraloncology.2026.107860&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-20&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41564692/'&gt;41564692&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Cervical lymph node metastasis (CLNM) is the most critical prognostic factor in oral squamous cell carcinoma (OSCC). To facilitate individualized risk assessment, this study aimed to develop and internally validate a novel prediction model. We retrospectively analyzed 3723 patients with OSCC from a single center (2012-2023), with 2792 eligible patients randomly allocated to a training (n¬†=¬†1954) and a validation set (n¬†=¬†838). A rigorous variable selection process was employed, where predictors significant in univariable analysis were entered into a multivariable logistic regression model that utilized a stepwise forward and backward elimination procedure to identify the final set of predictors. Six factors were ultimately incorporated into the nomogram: clinical T stage, clinical N stage, histological grade, perineural invasion, time from onset to treatment, and alcohol consumption. The model demonstrated good discrimination in both training (AUC = 0.780) and validation (AUC = 0.744), excellent calibration, and clinical utility. In conclusion, this internally validated nomogram accurately predicts CLNM risk and can aid in tailoring neck management, pending external validation.</description>
    </item>
    <item>
      <title>#8 [70/100] Molecular Profiling and Real-World Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41543354/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41543354/</guid>
      <dc:creator>Chirra M, Elliott A, Shaikh H, McGrath J, El-Gamal D, Karnezis AN, Abdulla FR, Ikpeazu C, Leddon J, Sukari A, et al.</dc:creator>
      <pubDate>Fri, 16 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large cohort (n=1348) with real-world outcomes and molecular profiling of BRAF V600E-mutated papillary thyroid cancer, providing important insights into treatment effectiveness, although it lacks the rigor of a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Chirra M, Elliott A, Shaikh H, McGrath J, El-Gamal D, Karnezis AN, Abdulla FR, Ikpeazu C, Leddon J, Sukari A, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Clinical cancer research : an official journal of the American Association for Cancer Research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/1078-0432.CCR-25-3932'&gt;10.1158/1078-0432.CCR-25-3932&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41543354/'&gt;41543354&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;INTRODUCTION: Radioactive iodine refractory papillary thyroid cancers (PTC) containing BRAF-V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared to tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF-mut and BRAF-wildtype (wt) PTC. METHODS: Thyroid tumor samples underwent DNA/RNA next-gen sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using QuanTIseq. Insurance claims data was used to infer real-world overall survival (OS) and time on treatment. RESULTS: A total of 1348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF-V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%), and more prevalent in BRAF-mut versus (vs) BRAF-wt. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-wt PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, p&lt;0.001) and had significantly higher IFNŒ≥ scores. OS was not significantly different between patients with BRAF-mut vs wt PTC. Systemic treatment (BRAF/MEKi, TKI or IO) was not associated with significant differences in OS in‚ÄØBRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared to BRAF/MEKi or IO. CONCLUSIONS: BRAF-mut PTC is associated with a pro-inflammatory TME milieu compared to BRAF-wt PTC. However, in this limited data set, treatment choice was not associated with differences in OS in BRAF-mut PTC.</description>
    </item>
    <item>
      <title>#9 [70/100] Dual-scale fusion vision transformer model for vocal cord leukoplakia risk stratification: A multicenter study.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41547298/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41547298/</guid>
      <dc:creator>Huang JL, Li LJ, Zhu JQ, Dou LZ, Liu YM, Ke Y, Zhao YD, Wang ML, Wang JH, Zhang QM, et al.</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter study utilizes a large dataset and advanced AI technology for risk stratification of vocal cord leukoplakia, addressing an important clinical question with potential implications for diagnostic practices, though it is retrospective and not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Huang JL, Li LJ, Zhu JQ, Dou LZ, Liu YM, Ke Y, Zhao YD, Wang ML, Wang JH, Zhang QM, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; American journal of otolaryngology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.amjoto.2026.104789'&gt;10.1016/j.amjoto.2026.104789&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41547298/'&gt;41547298&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: This study aimed to develop an artificial intelligence (AI) system for accurate three-tier risk stratification of vocal cord leukoplakia (VCL), with particular focus on distinguishing high-risk lesions (severe dysplasia and carcinoma in situ) from low-risk and malignant lesions, while enhancing diagnostic performance among clinicians with limited experience. METHODS: This retrospective multicenter study analyzed 8510 laryngoscopic images from 743 patients across three tertiary hospitals in China. A dual-scale Vision Transformer (ViT) architecture was constructed, integrating multi-scale feature analysis with cross-attention fusion mechanisms. The model was rigorously evaluated through internal-external validation and a prospective reader study involving 12 endoscopists of varying expertise. RESULTS: The AI system demonstrated superior performance in three-tier classification, achieving F1-scores of 0.883 (95% CI: 0.869-0.896) and 0.861 (95% CI: 0.844-0.878) for high-risk lesion identification in internal and external validation, respectively. AI assistance significantly improved junior endoscopists' sensitivity from 67.1% to 81.4% (P¬†&lt;¬†0.001), effectively narrowing diagnostic performance disparities with senior experts. The system maintained robust generalizability across institutions, with 90.5% accuracy under heterogeneous imaging protocols. CONCLUSION: The proposed AI framework provides a clinically effective solution for reliable VCL risk stratification and reduces diagnostic variability between clinicians. Validated across multiple centers, this dual-scale ViT approach establishes a novel paradigm for laryngoscopic diagnosis and holds significant potential to standardize diagnostic workflows in resource-limited settings.</description>
    </item>
    <item>
      <title>#10 [65/100] Pretreatment Chromosomal Instability Correlates With Radiation Sensitivity in Squamous Cell Cancers.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41563231/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41563231/</guid>
      <dc:creator>Cosper PF, Paracha M, Jones KM, Hrycyniak L, Henderson L, Bryan A, Eyzaguirre D, McCunn E, Boulanger E, Wan J, et al.</dc:creator>
      <pubDate>Tue, 20 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The study explores the correlation between chromosomal instability and radiation sensitivity in head and neck cancer, providing novel insights that could have clinical implications, but it is based on in vitro experiments and lacks a large prospective clinical trial or definitive evidence to influence treatment guidelines.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cosper PF, Paracha M, Jones KM, Hrycyniak L, Henderson L, Bryan A, Eyzaguirre D, McCunn E, Boulanger E, Wan J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of radiation oncology, biology, physics | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.ijrobp.2025.12.014'&gt;10.1016/j.ijrobp.2025.12.014&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-20&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41563231/'&gt;41563231&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Continuous chromosome missegregation over successive mitotic divisions, known as chromosomal instability (CIN), is common in cancer. Though it has been associated with treatment resistance and poor prognosis, increasing CIN above a maximally tolerated threshold leads to cell death because of loss of essential chromosomes. Because radiation causes CIN, we hypothesize that pre-existing CIN sensitizes tumor cells to radiation therapy. METHODS AND MATERIALS: We induced mitotic defects that lead to CIN in FaDu (head and neck cancer, HNC) and HeLa (cervical) cells by knocking down or overexpressing the mitotic checkpoint protein mitotic arrest deficient 1 (Mad1), which induces lagging chromosomes. Radiation sensitivity was tested with clonogenic assays in vitro and tumor regression in patient-derived xenografts in vivo. MTT assays were used to determine the sensitivity of human papillomavirus (HPV) positive and HPV-negative HNC cells to docetaxel, and mitotic defects were quantified using immunofluorescence microscopy. Docetaxel-induced mitotic errors and tumor growth delay were evaluated in vivo. Six-chromosome fluorescence in situ hybridization was used to quantify CIN in a cohort of patients with laryngeal cancer treated with definitive radiation. RESULTS: Here, we show in two tissue contexts using engineered isogenic cancer cell lines that higher rates of chromosome missegregation sensitize to ionizing radiation, which itself induces mitotic errors. Consistent with this result, higher rates of anaphase defects in HPV-positive and HPV-negative HNC patient-derived xenograft tumors correlate with response to radiation. Moreover, laryngeal tumors with higher CIN before treatment tend to have an improved response to radiation therapy in the clinic. Furthermore, we show that docetaxel, a microtubule-stabilizing drug commonly used in combination with radiation, causes cell death and radiosensitizes cells by inducing abnormal multipolar spindles rather than causing mitotic arrest. CONCLUSIONS: These results mechanistically implicate CIN as an inducer of radiation response and provide evidence that increasing the rate of CIN is a rational method to enhance radiation sensitivity, which has significant implications for personalized therapy.</description>
    </item>
  </channel>
</rss>
